Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Pemetrexed Plus Gemcitabine vs Standard Regimens in Relapsed NSCLC
NCT00356525Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Sep 2006; status: terminated.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00356525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356525.